| Name | Barnidipine hydrochloride |
| Description | Barnidipine hydrochloride (YM-09730-5 hydrochloride) is a dihydropyridine calcium channel blocker that has an IC50 value of 0.35 nM in potassium-induced tonic contraction of pig coronary artery |
| Animal Research | Forty-one patients (mean age 69 ± 17 years, 18 females) with previously diagnosed OSA (by reduced channel home-based polysomnography) who were not being treated with continuous positive airway pressure (CPAP) because of contraindications or because of patient intolerance or rejection were evaluated. Non-dipper status was defined as the presence of a nighttime fall in systolic blood pressure (BP) which was < 10% that of daytime systolic BP as observed in a previous ambulatory blood pressure (ABP) monitoring. OSA was defined according to the presence of 5 or more episodes per hour of apnoea, hypopnoea or arousal due to respiratory effort. The reproducibility of non-dipping status was confirmed through a second 24-h ABP monitoring performed at baseline. On top of the previous stable treatment regimen (which excluded calcium-channel blockers), a 10 mg dosing of barnidipine hydrochloride at bedtime was added to all subjects during a 12-week period[2]. |
| In vivo | Barnidipine demonstrates antihypertensive activity by reducing peripheral vascular resistance. It decreases blood pressure in spontaneously hypertensive rats when administered orally at 1 and 3 mg/kg per day[1]. Formulations containing barnidipine have been used as a treatment for hypertension. In obstructive sleep apnea patients with non-dipper pattern hypertension, barnidipine reduced mean nighttime systolic and diastolic arterial blood pressure[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (9.47 mM), Sonication is recommended.
DMSO : 250 mg/mL (473.48 mM), Sonication is recommended.
|
| Keywords | YM-09730-5 Hydrochloride | Mepirodipine | Inhibitor | inhibit | CalciumChannel | Calcium Channel | Ca2+ channels | Ca channels | Barnidipine Hydrochloride | Barnidipine hydrochloride | Barnidipine |
| Inhibitors Related | Nisoldipine | Diltiazem hydrochloride | Levetiracetam | L-Ascorbic acid | L-Phenylalanine | D-Menthol | Ethyl cinnamate | L-Ascorbic acid sodium salt | 1-Octanol | 2-Nitrobenzoic acid | Nifedipine | Otilonium bromide |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Neuroprotective Compound Library | Anti-Cancer Approved Drug Library | Metabolism Compound Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-COVID-19 Compound Library | Anti-Cancer Drug Library |
United States
